pISSN 2671-8790 eISSN 2671-8804


Article View

Korean J Transplant 2023; 37(1): 76-78

Published online March 31, 2023


© The Korean Society for Transplantation

Super-fast-track discharge of liver transplant recipients

Sapana Verma1 , Lalit Kumar Das2 , Selva Kumar Naganathan1

1Liver Transplant Unit, Apollo Institute of Liver Sciences, Apollo Hospital, Chennai, India
2Department of HBP and Liver Transplantation, Shahid Dharmabhakta National Transplant Center, Kathmandu, Nepal

Correspondence to: Sapana Verma
Liver Transplant Unit, Apollo Institute of Liver Sciences, Apollo Hospital, 21 Greams Ln, Off Greams Rd, Chennai 600006, India
E-mail: sapana_21@hotmail.com

Received: January 9, 2023; Revised: February 22, 2023; Accepted: February 24, 2023

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infectious complications are the leading cause of morbidity and mortality after liver transplantation (LT) in our region, especially hospital-borne infections [1,2]. Furthermore, a lack of medical insurance adds a tremendous financial burden when these patients’ stay is prolonged for the management of multiple complications. Enhanced recovery after surgery (ERAS) has enabled fast-track LT at many centers around the world [3-5]. We, therefore, changed our transplant protocols for selected patients and applied a super-fast-track pathway (preoperation to discharge). Our patients were discharged at 5.5±1.6 days after LT on average. All are alive, are receiving regular follow-up, and have not experienced any complications until the time of writing this report. We therefore briefly present our super-fast-track discharge protocol. Nine blood group-compatible liver transplants were done between October 2021 and August 2022. Among them, three were living-donor LT and six were deceased-donor LT. Patients’ preoperative and perioperative demographics are shown in Table 1 and Fig. 1.

Table 1. Background demographic, preoperative, and postoperative characteristics of all recipients


Age (yr)49426750445149395249.28
Primary etiologyCryptogenicNASHNASHAlcoholicCryptogenicNASH with HCCCryptogenicAlcoholicNASH--
Pretransplant decompensationAscites, jaundice, TIPS failureUGI bleed, jaundice, ascitesAscites, jaundice, HRSAscites, jaundice, recurrent HEUGI bleed, jaundiceJaundice, HCC within the Milan criteriaAscites, jaundiceAscites, jaundice, recurrent HEAscites, jaundice--
Total blood transfusion (1 unit=250 mL)3122131211.80.8
Bench time (min)35302515312538324030.17.7
CIT+WIT (min)1969060572059314521519013964.7
Total bilirubin (mg/dL)
Postoperative day
Postoperative day 31.34.613.
At discharge0.920.
Tacrolimus level at discharge9.
Day of discharge4644468865.61.7

SD, standard deviation; NASH, non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma; DDLT, deceased donor liver transplantation; LDLT, living-donor LT; TIPS, transjugular intrahepatic portosystemic shunt; UGI, upper gastrointestinal; HRS, hepatorenal syndrome; HE, hepatic encephalopathy; MELD, model for end stage liver disease; CTP, Child-Turcotte-Pugh score; CIT, cold ischemic time; WIT, warm ischemic time.

Figure 1. (A) Trends in total bilirubin, (B) serum glutamic pyruvic transaminase (SGPT), and (C) serum glutamic-oxaloacetic transaminase (SGOT) in all nine patients at postoperative day (POD) 0, POD 3, and at the time of discharge.

Preoperative: our main aim was to optimize all patients’ conditions prior to LT. In short, they were given hepatoprotective medication and intravenous (IV) albumin (20%, 100 mL; Baxter) once a week and followed up once a week with blood biochemistry reports, and the medication was adjusted accordingly. Decompensation was managed quickly and the aim was to keep the patients infection-free during the preoperative period. Nutritional build-up was done as much as possible (high protein [60 g/day], no salt, and fluid restricted to <1.5 L per day).

Intraoperative: the anesthesia protocol was similar to that described in a previous study [3]. Surgery was performed according to the standard protocol. The total blood transfusion was minimized (1.8±0.8 units). The bench time was kept short (30.1±7.7 minutes). Induction was done with an IV injection of Solu-Medrol (500 mg; Pfizer). All nine patients were extubated on the table and then transferred to the liver intensive care unit (LICU) with continuous monitoring.

Postoperative: one critical care physician and a 1:1 nursing-to-patient ratio was maintained until the patient was discharged from the LICU. Early ambulation and oral intake were started 12 hours later. Liver Doppler ultrasonography and blood biochemistry were done twice a day until postoperative day (POD) 2. Central and arterial lines and the Foley catheter were removed on POD 2, and thereafter noninvasive monitoring was done until discharge. Immunosuppression (calcineurin inhibitors+mycophenolate mofetil) was started early, as soon as the lactate level was <2 mmol/L. IV Solu-Medrol was tapered and converted to oral prednisolone from POD 4. IV antibiotics were given until POD 3, until the trough level was adjusted to 8–10 ng/mL, and then converted to oral. Education for the patient and family on medication, hygiene, nutrition, and wound care was started on POD 1, and the patient was discharged with a home care nurse. Follow-up was done after 3 days with reports, and the medication was adjusted if needed. Then, patients were followed up once a week until 1 month, twice a week until 3 months, and thereafter at 3-month intervals until 1 year. In conclusion, herein we report our brief protocol for super-fast-track discharge of selected LT patients.


Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Author Contributions

Conceptualization: all authors. Data curation: SV. Formal analysis: SV, LKD. Supervision: SKN. Writing–original draft: SV, LKD. Writing–review & editing: all authors. All authors read and approved the final manuscript.


  1. Varghese J, Gomathy N, Rajashekhar P, Venugopal K, Olithselvan A, Vivekanandan S, et al. Perioperative bacterial infections in deceased donor and living donor liver transplant recipients. J Clin Exp Hepatol 2012;2:35-41.
    Pubmed CrossRef
  2. Khillan V, Kale P, Pamecha V, Rathor N, Sarin SK. Infections in live donor liver transplant recipients: a study of timeline, aetiology and antimicrobial resistance of bacterial and fungal infections from the developing world. Indian J Med Microbiol 2017;35:604-6.
    Pubmed CrossRef
  3. Rodríguez-Laiz GP, Melgar-Requena P, Alcázar-López CF, Franco-Campello M, Villodre-Tudela C, Pascual-Bartolomé S, et al. Fast-track liver transplantation: six-year prospective cohort study with an enhanced recovery after surgery (ERAS) protocol. World J Surg 2021;45:1262-71.
    Pubmed KoreaMed CrossRef
  4. Sellers D, Sapisochin G, Selzner N, McCluskey SA. Enhanced recovery for liver transplantation: a first step on a long road. Transplantation 2022;106:460-1.
    Pubmed CrossRef
  5. Pollok JM, Tinguely P, Berenguer M, Niemann CU, Raptis DA, Spiro M, et al. Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference. Lancet Gastroenterol Hepatol 2023;8:81-94.
    Pubmed CrossRef